Improving lung cancer treatment by targeting genetic changes
Targeting epigenetic heterogeneity to improve lung cancer immunotherapy response
This study is looking at ways to make immunotherapy work better for people with squamous non-small cell lung cancer by adding a special treatment that helps boost the immune response, and it will explore how this combination can improve results for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10654703 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of immunotherapy for patients with squamous non-small cell lung cancer (NSCLC) by using an epigenetic inhibitor. The approach focuses on combining this inhibitor with existing treatments that target the PD1/PD-L1 interaction, which is crucial for T cells to attack tumor cells. By studying both mouse models and patient-derived organoid cultures, the research aims to understand how these treatments can increase the response rate and identify the mechanisms behind successful and unsuccessful outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with late-stage squamous non-small cell lung cancer who have not responded well to existing treatments.
Not a fit: Patients with other types of lung cancer or those who have not yet received treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment responses for patients with squamous lung cancer, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promising results with similar approaches, indicating potential for significant advancements in lung cancer treatment.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Brainson, Christine Fillmore — University of Kentucky
- Study coordinator: Brainson, Christine Fillmore
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.